Lung Adenocarcinoma Harboring EGFR T790M and In Trans C797S Responds to Combination Therapy of First- and Third-Generation EGFR TKIs and Shifts Allelic Configuration at Resistance

Journal of Thoracic Oncology

Volumn 12, Issue 11, 2017, Pages 1723-1727

  Wang, Zhen ^a   Yang, Jin Ji ^a   Huang, Jie ^a   Ye, Jun Yi ^b   Zhang, Xu Chao ^a   Tu, Hai Yan ^a   Han Zhang, Han ^b   Wu, Yi Long ^a  

^a GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^b Burning Rock Biotech ^*  (China)

Author keywords

EGFR C797S; EGFR T790M; Lung cancer; Osimertinib; Resistance mechanisms

Indexed keywords

AFATINIB; ANTINEOPLASTIC AGENT; AVITINIB; BEVACIZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FLUORODEOXYGLUCOSE F 18; OSIMERTINIB; PACLITAXEL; UNCLASSIFIED DRUG; PROTEIN KINASE INHIBITOR;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; ARTICLE; BLOOD SAMPLING; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CLINICAL ARTICLE; CONTROLLED STUDY; COUGHING; DNA SEQUENCE; DYSPNEA; EGFR GENE; EXON; FATIGUE; GENE DELETION; GENE LOCATION; HUMAN; HUMAN TISSUE; JAUNDICE; LUNG ADENOCARCINOMA; MALAISE; MALE; MUTATIONAL ANALYSIS; NEEDLE BIOPSY; PLEURA EFFUSION; POLYMERASE CHAIN REACTION; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REPEAT PROCEDURE; SEQUENCE ANALYSIS; TREATMENT RESPONSE; TUMOR BIOPSY; X-RAY COMPUTED TOMOGRAPHY; ADENOCARCINOMA; CASE REPORT; DRUG EFFECT; DRUG RESISTANCE; GENETICS; LUNG TUMOR; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROCEDURES;

ADENOCARCINOMA; ADULT; COMBINED MODALITY THERAPY; DRUG RESISTANCE, NEOPLASM; HUMANS; LUNG NEOPLASMS; MALE; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 85025434851     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1016/j.jtho.2017.06.017     Document Type: Article

References (10)

1. Wu, Y.L., Zhou, C., Liam, C.K., et al. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study. Ann Oncol 26 (2015), 1883–1889.
2. Arcila, M.E., Oxnard, G.R., Nafa, K., et al. Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. Clin Cancer Res 17 (2011), 1169–1180.
3. Sequist, L.V., Waltman, B.A., Dias-Santagata, D., et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med, 3, 2011, 75ra26.
4. Jänne, P.A., Yang, J.C., Kim, D.W., et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med 372 (2015), 1689–1699.
5. Niederst, M.J., Hu, H., Mulvey, H.E., et al. The allelic context of the C797S mutation acquired upon treatment with third-generation EGFR inhibitors impacts sensitivity to subsequent treatment strategies. Clin Cancer Res 21 (2015), 3924–3933.
6. Wang, Z., Wu, Y.L., Zhang, G.C., Zhou, Q., Xu, C.R., Guo, A.L., EGFR/KRAS mutations and gefitinib therapy in Chinese NSCLC patients. Onkologie 31 (2008), 174–178.
7. Mao, X., Zhang, Z., Zheng, X., et al. Capture-based targeted ultradeep sequencing in paired tissue and plasma samples demonstrates differential subclonal ctDNA-releasing capability in advanced lung cancer. J Thorac Oncol 12 (2017), 663–672.
8. Ercan, D., Choi, H.G., Yun, C.H., et al. EGFR mutations and resistance to irreversible pyrimidine-based EGFR inhibitors. Clin Cancer Res 21 (2015), 3913–3923.
9. Godin-Heymann, N., Ulkus, L., Brannigan, B.W., et al. The T790M “gatekeeper” mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor. Mol Cancer Ther 7 (2008), 874–879.
10. Uchibori, K., Inase, N., Araki, M., et al. Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer. Nat Commun, 8, 2017, 14768.